Investment analysts at Numis Securities Ltd assumed coverage on shares of Allergy Therapeutics plc (LON:AGY) in a note issued to investors on Wednesday. The brokerage set a “buy” rating and a GBX 37 ($0.48) price target on the stock. Numis Securities Ltd’s price target points to a potential upside of 101.36% from the stock’s current price.

A number of other analysts have also commented on AGY. Panmure Gordon restated a “buy” rating and issued a GBX 53 ($0.69) price target on shares of Allergy Therapeutics plc in a report on Thursday, July 14th. Stifel Nicolaus restated a “buy” rating and issued a GBX 72 ($0.94) price target on shares of Allergy Therapeutics plc in a report on Friday, July 8th.

Shares of Allergy Therapeutics plc (LON:AGY) opened at 18.30 on Wednesday. The company’s market cap is GBX 102.39 million. Allergy Therapeutics plc has a 52 week low of GBX 18.00 and a 52 week high of GBX 34.82. The company’s 50-day moving average price is GBX 18.83 and its 200 day moving average price is GBX 22.82.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About Allergy Therapeutics plc

Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with's FREE daily email newsletter.